Entity

Time filter

Source Type


Yang S.,Guizhou University | Yang S.,Sinphar Tian Li Pharmaceutical Co. | Yang S.,Yangtze River Pharmaceutical Group Co. | Liu M.,Guizhou University | And 4 more authors.
Medicinal Chemistry Research | Year: 2015

Cyrtomium fortumei (J.) Smith is an endemic species in China, which has been proved to be an important Chinese herbal medicine. However, chemical composition and bioactivity of essential oil (EO) of C. fortumei (J.) Smith leaves remain unclear. In present study, we isolated EO from the plant by supercritical carbon dioxide extraction assay (SFE-CO2), and investigated on cancer cells MGC-803, MCF-7, BGC-823, Bcap-37, A375, and A549 in vitro by MTT assay. 26 compounds were identified by GC-MS analysis, and the EO showed significant antitumor activities against MGC-803, Bcap-37, and A549 cancer cell lines (IC50 values ranging from 0.15 to 0.24 mg/mL), and the activities of its main component were also studied. Subsequent fluorescence staining and flow cytometry analysis indicated that the EO could induce apoptosis in MGC-803, Bcap-37, and A549 cell lines, and the apoptosis ratios reached 26.44 % after 48 h of treatment at 0.15 mg/mL in MGC-803 cells. Caspase 3 activity in MGC-803 cells was also determined when the cells treated with the oil, and the activity of caspase 3 enzyme was increased compared to the control. This study suggests that the EO isolated from C. fortumei (J.) Smith could inhibit the growth of human carcinoma cells, and it could induce apoptosis of cancer cells. © 2014 Springer Science+Business Media New York. Source


Patent
Sinphar Tian Li Pharmaceutical Co. | Date: 2010-04-30

A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a


Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.


Patent
Sinphar Tian Li Pharmaceutical Co. | Date: 2010-08-10

A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a


A pharmaceutical composition containing isoacteoside to the acteoside is provided, which is able to inhibit formation, accumulation or aggregation of amyloid peptides, and is thus useful in preventing or treating amyloid beta peptide-associated diseases or conditions, wherein a weight ratio of the isoacteoside to the acteoside is 4:1 to 1:4.

Discover hidden collaborations